Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis
| Autor: | Shuai Xue, Li Zhang, Sensen Su, Jie Hou, Jia Li |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Aging
medicine.medical_specialty Side effect Anemia Glycine Placebo Gastroenterology law.invention Hemoglobins Randomized controlled trial law Internal medicine hemic and lymphatic diseases medicine Animals Humans Renal Insufficiency Chronic business.industry roxadustat Cell Biology medicine.disease Isoquinolines meta-analysis Erythropoietin Relative risk Hematinics Hemoglobin business chronic kidney disease Kidney disease medicine.drug Research Paper |
| Zdroj: | Aging (Albany NY) |
| ISSN: | 1945-4589 |
| Popis: | Background: Anemia is a common complication of chronic kidney disease (CKD). Treating renal anemia with erythropoiesis-stimulating agents (ESAs) or erythropoietin analogs is effective but has side effects. Therefore, we performed a meta-analysis to assess the efficacy and safety of roxadustat in treating CKD-induced anemia. Methods: We searched publications online and conducted a meta-analysis and calculated relative risks with 95% confidence intervals (CIs) for dichotomous data and mean differences (MD) with 95% CIs for continuous data. Results: Of 110 articles, nine were included that contained 12 data sets and 11 randomized control trials on roxadustat. In the non-dialysis-dependent (NDD) high-dose/low-dose subgroups, the change in hemoglobin (Hb) levels was significantly higher in the roxadustat group than in the placebo group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|